Table 4.
Acute and Late Toxicity
| Toxicity | No. of Evaluable Patients | Grade 2 |
Grade 3 |
||
|---|---|---|---|---|---|
| No. of Observed Toxicities | Percentage of Patients With Toxicities | No. of Observed Toxicities | Percentage of Patients With Toxicities | ||
| Acute toxicity | 57 | ||||
| Orbital | 13 | ||||
| Radiation dermatitis | 5 | 38 | 1 | 8 | |
| Dry eye | 2 | 15 | 1 | 8 | |
| Head and neck | 31 | ||||
| Odynophagia | 4 | 13 | 3 | 10 | |
| Radiation dermatitis | 10 | 32 | 2 | 6 | |
| Mucositis | 19 | 61 | 1 | 3 | |
| Dry eye | 2 | 6 | 1 | 3 | |
| Otitis | 1 | 3 | 1 | 3 | |
| GI/genitourinary | 8 | ||||
| Elevated liver function tests | 0 | 0 | 1 | 13 | |
| Radiation dermatitis | 2 | 25 | 0 | 0 | |
| Diarrhea | 2 | 25 | 0 | 0 | |
| Bladder spasm | 1 | 13 | 0 | 0 | |
| Painful bowel movement | 1 | 13 | 0 | 0 | |
| Trunk/extremity | 5 | ||||
| Radiation dermatitis | 1 | 20 | 2 | 40 | |
| All Patients | 57 | ||||
| Fatigue | 3 | 5 | 0 | 0 | |
| Total | 57 | 61 | 13 | 17 | |
| Late toxicity | 43 | ||||
| Orbital | 12 | ||||
| Cataract | 0 | 0 | 1 | 8 | |
| Dry eye | 2 | 17 | 0 | 0 | |
| Facial hypoplasia/asymmetry | 1 | 8 | 0 | 0 | |
| Epistaxis | 1 | 8 | 0 | 0 | |
| Dry skin | 1 | 8 | 0 | 0 | |
| Head and neck | 21 | ||||
| Chronic otitis | 1 | 5 | 1 | 5 | |
| Retinopathy | 0 | 0 | 1 | 5 | |
| Endocrine abnormalities | 3 | 14 | 0 | 0 | |
| Cerumen buildup | 3 | 14 | 0 | 0 | |
| Facial hypoplasia/asymmetry | 2 | 10 | 0 | 0 | |
| Hearing loss (unilateral) | 2 | 10 | 0 | 0 | |
| Cavernoma | 1 | 5 | 0 | 0 | |
| Cognitive disturbance | 1 | 5 | 0 | 0 | |
| Dry eye | 1 | 5 | 0 | 0 | |
| Trunk/extremity | 4 | ||||
| Skeletal or muscle defect | 1 | 25 | 0 | 0 | |
| Total | 20 | 28 | 3 | 7 | |
NOTE. Fifty-seven acute grade 2 toxicities developed in 35 patients, 13 acute grade 3 toxicities developed in 11 patients, 20 late grade 2 toxicities developed in 12 patients, and 3 late grade 3 toxicities developed in three patients.